Latest From Antabio SAS
With biopharma venture capital investment of $9.67bn during the first half, 2018's total is on track to beat 2017 in the third quarter. IPOs, one of the factors fueling VC investment, continue to boom with five more drug developers slated to go public this week.
The latest biopharma industry appointments include C-suite hires at Hikma, Ipsen, Sinclair PeptiDream, Targovax, Nicox, Moderna, Antabio and Perrigo; as well as a supervisory board appointment at Kiadis.
October was an active fundraising month for both start-up biopharma companies and more established privately held firms, ranging from $3m for Appili's drug for anaerobic infections to $270m for Harmony's rare disease programs.
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Antabio SAS
- Senior Management
Marc Lemonnier, PhD, CEO
Gordon Waldron, CFO
Martin Everett, PhD, CSO
Magdalena Zalacain, PhD, Head, Preclinical Dev.
Carole Sable, MD, Head, Clinical Dev.
Helmuth van Es, CBO
- Contact Info
Phone: (33) 633 34 39 76
Rue Pierre et Marie Curie
P.O. Box 28262 Labege, 31682
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.